期刊文献+

尼莫地平联合丹参川芎嗪对妊娠期高血压疾病患者凝血功能、Hcy、PLGF水平的影响 被引量:5

Effects of nimodipine combined with salviae miltiorrhizae and ligustrazine on coagulation function,Hcy and PLGF levels in patients with hypertensive disorder complicating pregnancy
下载PDF
导出
摘要 目的探讨尼莫地平联合丹参川芎嗪对妊娠期高血压疾病患者凝血功能、同型半胱氨酸(Hcy)、胎盘生长因子(PLGF)水平的影响。方法将88例妊娠期高血压疾病患者随机分为对照组和观察组,各44例。对照组在硫酸镁+拉贝洛尔治疗基础上应用尼莫地平治疗,观察组则在对照组治疗基础上联合丹参川芎嗪治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组舒张压、收缩压、FIB及Hcy水平均降低,PT及APTT均延长,PLGF水平均升高,且观察组优于对照组(P<0.05)。结论尼莫地平联合丹参川芎嗪治疗妊娠期高血压疾病,能显著提高临床效果,改善患者的凝血功能及Hcy、PLGF水平。 Objective To explore the effects of nimodipine combined with salviae miltiorrhizae and ligustrazine on coagulation function,homocysteine(Hcy)and placental growth factor(PLGF)levels in patients with hypertensive disorder complicating pregnancy.Methods Eighty-eight patients with hypertensive disorder complicating pregnancy were randomly divided into control group and observation group,with 44 cases in each group.The control group was treated with nimodipine on the basis of magnesium sulfate+labetalol,while the observation group was treated with salviae miltiorrhizae and ligustrazine on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the diastolic blood pressure,systolic blood pressure,FIB and Hcy levels of the two groups decreased,PT and APTT prolonged,PLGF level increased,and those of the observation group were better than the control group(P<0.05).Conclusion Nimodipine combined with salviae miltiorrhizae and ligustrazine in the treatment of hypertensive disorder complicating pregnancy can significantly improve the clinical efficacy,and ameliorate coagulation function and Hcy,PLGF levels of patients.
作者 肖萍萍 郭华娟 XIAO Pingping;GUO Huajuan(Obstetrics and Gynecology Department,Kaifeng Maternal and Child Health Care Hospital,Kaifeng 475000,China;Key Laboratory of Endocrinology,Kaifeng Maternal and Child Health Care Hospital,Kaifeng 475000,China)
出处 《临床医学研究与实践》 2021年第9期47-49,共3页 Clinical Research and Practice
关键词 妊娠期高血压疾病 丹参川芎嗪 尼莫地平 凝血功能 同型半胱氨酸 胎盘生长因子 hypertensive disorder complicating pregnancy salviae miltiorrhizae and ligustrazine nimodipine coagulation function homocysteine placental growth factor
  • 相关文献

参考文献11

二级参考文献130

  • 1肖丽,赵梅花,刘香环,李坤.丹参川芎嗪注射液对妊娠期高血压模型大鼠的疗效及胎盘细胞Cyclin B1和p21蛋白的影响[J].中国生化药物杂志,2014,34(6):55-58. 被引量:13
  • 2American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy.Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy [J]. Obstet Gynecol, 2013, 122(5):1122-1131.
  • 3Magee LA, Pels A, Helewa M, et al.Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary[J]. J Obstet Gynaecol Can, 2014, 36(5):416-441.
  • 4Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance[J]. BMJ, 2010, 341 :c2207.
  • 5Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014[J]. Aust N Z J Obstet Gynaecol, 2015, 55(1):11-16.
  • 6Campos-Outcah D Sr. US Preventive Services Task Force: the gold standard of evidence-based prevention[J]. J Fam Pract, 2005, 54(6):517-519.
  • 7Magee LA, Hdewa M, Momquin JM, et al. Diagnosis, evaluation,and management of the hypertensive disorders of pregnancy[J]. J Obstet Gynaeeol Can, 2008, 30 (Suppl): S1-48.
  • 8Cote AM, Brown MA, Laln E, et al. Diagnostic accuracy of urinary spot protein: creatiniue ratio for proteinuria in hypertensive pregnant women: systematic review[J]. BMJ, 2008, 336(7651): 1003-1006.
  • 9Churchill D, Beevers GD, Meher S, et al, Diuretics for preventing pre-eclampsia[J]. Cochrane Database Syst Rev, 2007, 24 (1):CD004451.
  • 10McCoy S, Baldwin K. Pharmacotherapeutie options for the treatment of preeelampsia[J]. Am J Health Syst Pharm, 2009, 66(4):337-344.

共引文献1391

同被引文献67

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部